Suzetrigine, sold under the brand name Journavx, is a medication used for pain management. [1][2] It is a non- opioid, small-molecule analgesic that works as a selective inhibitor of Na v …

Aug 2, 2023 · We describe the preclinical characterization of VX-548, an oral, highly selective inhibitor of Na V 1.8, and we report the results of two phase 2 trials evaluating the efficacy and...

Jan 31, 2025 · Journavx (suzetrigine, VX-548) pain-relieving medicine (analgesic) that works by selectively blocking a ion channel called Nav1.8. It is currently undergoing investigational trials …

Jan 31, 2025 · Journavx (suzetrigine) is a sodium channel blocker indicated for the treatment of moderate to severe acute pain in adults. Acute pain is a serious and potentially disabling …

Dec 19, 2024 · Suzetrigine is an investigational medicine for acute and peripheral neuropathic pain, including lumbosacral radiculopathy. N=218 patients*, randomized 1:1 suzetrigine vs. …

2 days ago · Not only did VX-548 fail to demonstrate superiority over Vicodin, but also that of the two most common oral opioids given following surgery, Percocet (oxycodone) and Vicodin – …

Aug 3, 2023 · The effect of VX-548, an oral, highly selective inhibitor of Na V 1.8, on control of acute pain is being studied. Methods: After establishing the selectivity of VX-548 for Na V 1.8 …

Nov 18, 2024 · VX-548 is a new oral NaV1.8-specific inhibitor that received United States Food and Drug Administration Fast Track and Breakthrough Therapy designations. Its efficacy was …

Jan 31, 2024 · The question is: How well does VX-548 work; the answer is unclear. In today's press release, the company announced Phase III results of VX-548, aka Suzetrigine, its novel …

Feb 12, 2024 · Vertex’s Na V 1.8 inhibitor VX-548 passed its phase III trials in abdominoplasty and bunionectomy, offering better pain relief than placebo to patients after these elective …